Skip to content
Educational information only. Not medical advice. We sell nothing and take no affiliate money.
By /
Peptide blendNo published researchNot FDA approved

GLOW blend

Premixed blend usually combining BPC-157, TB-500 and GHK-Cu

Last reviewed October 27, 2026 · 22 sources · Written for general readers · Compare with another compound →

The bottom line

The name GLOW is used online for premixed vials that typically combine BPC-157, TB-500 and GHK-Cu, but no official source defines it, and FDA has found that products sold under peptide nicknames differ from one another.[1] No study has tested this three peptide mix in cells, animals or people. The closest test, in rats, found BPC-157 plus TB-500 worked no better than TB-500 alone.[2] None of the ingredients is an approved drug, and the new HHS compounding policy covers only products with a single active ingredient.[3]

Where the evidence stands

What it is

The name GLOW is used online for premixed vials that typically combine BPC-157, TB-500 and GHK-Cu. We found no FDA document, journal article or major news report that defines the name or sets a standard recipe, so the ingredients, amounts and quality can differ from one product to the next. FDA's 2026 review found BPC-157 sold in multi ingredient products, including nasal sprays and injections combined with TB-500.[1] NPR reported that injectable GHK-Cu is often stacked with other repair peptides.[7]

BPC-157 is a lab made 15 amino acid peptide with a large animal record for tendon, muscle, gut and bone healing.[10] In people, a 2026 systematic review found only three small uncontrolled studies with 30 people in total and rated the evidence very low certainty.[11] Its only placebo controlled trial, in ulcerative colitis, showed no clear benefit.[1]

TB-500 is a lab made seven amino acid piece of thymosin beta 4, a natural protein that helps cells build their internal skeleton.[4] FDA found no human study of TB-500 by any route and no toxicity studies at all.[4] The small human trials people cite used the full parent protein, as a skin gel or eye drops, with mixed results.[12][13]

GHK-Cu is a tiny copper binding peptide found naturally in human blood, and supporters note that levels fall by more than half between age 20 and age 60.[5] Small cream studies suggest modest skin benefits, often without a placebo group.[6] A copper peptide wound gel failed two large trials in 511 people with diabetic foot ulcers.[14] NPR reported in 2026 that no published human data show injected GHK-Cu is safe or effective.[7]

Name
GLOW blend (Premixed blend usually combining BPC-157, TB-500 and GHK-Cu)
Other names
GLOW stack, GLOW peptide
Type
Peptide blend

What it does in the body

A GLOW vial is not one substance. It is a mix of three separate peptides that each act differently in animal and lab studies: BPC-157 is linked to blood vessel growth signals, TB-500 copies the actin grabbing part of thymosin beta 4, and GHK-Cu is a natural copper carrying peptide. No one has measured what they do together in the body.[4][5]

This is the biology, area by area. A change measured in the body, like a higher blood level, does not always mean a person feels a benefit. The claims check below covers that.

Skin and hair

Measured in people

The skin claims rest on GHK-Cu. In a small study of 20 women who put GHK-Cu, vitamin C or retinoic acid cream on the thigh for a month, skin samples showed more collagen in 70% of those using GHK-Cu, versus 50% and 40% with the other creams, and there was no placebo group.[6] Those were creams on the skin. Nobody has measured what an injected mix does to the skin.[7]

Joints and tendons

Seen in animals

In 32 rats with repaired Achilles tendons, TB-500 alone made tendons about 39% harder to break than no treatment. BPC-157 plus TB-500 together did not beat either one alone, and the authors suggested the two may act on the same pathways.[2] GHK-Cu was not part of that test.[2]

Heart and blood vessels

Seen in animals

BPC-157 raised VEGFR2, a receptor that tells cells to grow new blood vessels, and sped return of blood flow in rats with blocked leg arteries.[8] Whether mixing it with other peptides changes this has never been studied.[1]

Cells and tissue repair

Lab finding

TB-500 copies the part of thymosin beta 4 thought to grab actin, a building block of the cell skeleton that cells use to move.[4] In lab studies, GHK-Cu raised the collagen and elastin made by skin cells.[5] These are separate actions measured one peptide at a time.

Absorption and breakdown

Seen in animals

Each peptide is broken down at its own speed. In rats and dogs given BPC-157 into a vein, half was gone in about 5 to 15 minutes.[1] In horses given TB-500 under the skin, blood levels became unmeasurable within 6 to 10 hours.[4] No one has measured how the mixed peptides are absorbed or broken down together.[4]

How it works

Each ingredient has its own proposed mechanism. None has been tested as part of a mix.

  • BPC-157 raised VEGFR2, a blood vessel growth receptor, and switched on nitric oxide signals in cells and rats.[8]
  • TB-500 copies the actin binding stretch of thymosin beta 4. In a dish, TB-500 itself did not speed closure of scratched skin cells, though one of its breakdown pieces did.[4]
  • GHK-Cu raised collagen and elastin production by skin cells in lab studies and shifted the activity of many repair genes.[5]
  • In rats, combining BPC-157 with TB-500 did not add up to a bigger effect, which the authors thought might mean both work through shared pathways.[2]

Nobody has tested whether these ingredients interact, add up or cancel out when mixed.

What the research shows

We keep animal and human evidence apart. A result in animals is a reason to study something in people, not proof that it works in people.

Animal and lab studies

Animal data exists for the parts, not the mix

  • We found no animal or cell study of the full GLOW mix. The 2026 rat study below is the only one we found that combined any of its ingredients, and its authors cited no earlier combination study.[2]
  • The only study combining any of its ingredients tested BPC-157 and TB-500 in 32 rats with repaired Achilles tendons. TB-500 alone gave the strongest results, and the pair together added nothing over either alone.[2]
  • For BPC-157, a 2025 systematic review found 36 studies of muscle, tendon, ligament and bone healing, of which 35 were in animals or cells.[10]
  • For GHK-Cu, studies in rabbits, rats, pigs and mice reported better wound healing, including in diabetic rats.[5]
  • For TB-500, healing data in living animals is limited to that single rat tendon study and a mouse skin study of a slightly different chain.[2][4]

Limit: Results for single peptides cannot tell you what happens when they are mixed in one vial.

Human studies

No human study of GLOW exists

  • Nobody has published a study of the three peptide GLOW mix in people. FDA's 2026 review found no human studies at all for TB-500, and its complaint system held two reports about BPC-157 and TB-500 blends with no safety details.[4]
  • The closest human data is a 2021 chart review at one Florida clinic. Of 16 people with knee pain reached by phone, 4 had received BPC-157 mixed with thymosin beta 4 into the knee and 3 of them said their pain improved. There was no comparison group, exam or standard score.[9]
  • A 2026 report described three dental patients with jaw nerve damage given gum injections of a mix including BPC-157 and TB-500, plus another peptide, a steroid and a numbing drug, over four weeks. All regained most feeling and no side effects were recorded, but natural recovery could not be ruled out and no single ingredient could be credited.[15]
  • An FDA adverse event report described a 40 year old woman who injected a research labelled BPC-157 and TB-500 blend under the skin. After about a week her skin and gums darkened, the change came back when she used it again, and it faded after she stopped. FDA said the two peptide mix made it impossible to tell which caused it.[1]
  • For BPC-157 alone, three small uncontrolled studies cover 30 people with knee pain, bladder pain or an IV safety check. Most reported improvement and no side effects, but the evidence was rated very low certainty.[11]
  • For GHK-Cu, human studies are small cream trials on the skin. The one large drug program, a copper peptide wound gel tested in 511 people with diabetic foot ulcers, did no better than placebo.[6][14]
  • For TB-500, the only human trials used the full parent protein as a skin gel in 73 people with leg ulcers and as eye drops in 72 people with dry eye, with mixed results and no injections.[12][13]

Limit: Everything people report about this blend comes from online stories, not from studies, so its effects and side effects in people are unknown.

Claims check

The most common claims about this compound, and what studies actually found. Verdicts rate the evidence, not whether you should use it.

Gives glowing, younger looking skin

Not tested

No study has tested GLOW for skin. The skin evidence belongs to GHK-Cu used as a cream: small studies in women reported thicker, firmer skin and new collagen, often without a placebo group.[6] No human trial has tested injected GHK-Cu, alone or mixed.[7]

Speeds healing of tendons and injuries

Only in animals

Only part of the mix has been tested together. In rats with repaired Achilles tendons, TB-500 alone made tendons stronger, while BPC-157 plus TB-500 gave no extra benefit over either alone.[2] In people, a clinic chart review found 3 of 4 patients given BPC-157 mixed with thymosin beta 4 in the knee said their pain improved, with no comparison group.[9]

The three peptides boost each other

Not tested

No study has tested whether the three peptides add up, interact or cancel each other out. The one study that combined two of them, BPC-157 and TB-500 in rats, found no added benefit from the pair.[2]

Reduces wrinkles and builds collagen

Not tested

This has never been tested for the blend. A randomized study of a GHK-Cu serum reported less wrinkle volume after 8 weeks than a plain serum, but that was a skin product, not an injection or a mix.[5] NPR reported that human GHK-Cu studies mostly tested small, industry funded creams.[7]

Calms inflammation and gut problems

Not tested

No study has tested the blend for inflammation. BPC-157 did not beat placebo clearly in its only human gut trial, in about 53 people with ulcerative colitis.[1]

Is safe because the peptides are natural

Not tested

No safety study of the mix exists. TB-500 has no toxicity studies of any kind.[4] BPC-157 and TB-500 are made in a lab, not taken from the body, and FDA warns injected peptides can trigger immune reactions.[1][4]

Known risks and side effects

  • An untested combination. No safety study of the GLOW mix exists, and TB-500 has no toxicity studies of any kind.[4] FDA warns that injected peptides can trigger immune reactions, made worse by clumping and impurities.[1]
  • Side effects reported with blends. An FDA report describes skin and gum darkening that came back each time a woman used a BPC-157 and TB-500 blend.[1] A clinician told NPR he saw injection site infections and, in some patients who self injected GHK-Cu, raised liver enzymes and copper levels, though the cause was unclear.[7]
  • Unregulated products. Blends are sold online as research products, outside the pharmacy system. FDA found multi ingredient BPC-157 products labelled for research only.[1] The 2026 HHS compounding policy covers only single ingredient products, so a premixed blend does not qualify.[3]
  • Long term risk is unknown. Two ingredients are thought to boost blood vessel growth or cell movement, which a 2026 journal review warned could in theory help an undetected tumor grow or spread.[16]
  • Banned in sport. The World Anti Doping Agency bans BPC-157 under S0 and TB-500 under S2.3 at all times, on both the 2026 list and the 2027 list that starts January 1, 2027.[17][18]

Regulatory status

Today: None of the ingredients in a GLOW blend is an approved drug. In July 2026 FDA's Pharmacy Compounding Advisory Committee voted 8 to 6 with one abstention to recommend adding BPC-157 and TB-500 to the 503A compounding list, against FDA staff advice.[19] On October 28, 2026 HHS filed a policy saying it will not act against licensed pharmacies that compound BPC-157, TB-500 and four other peptides under strict conditions, but each product must contain only one active ingredient, so premixed blends are not covered.[3][20] GHK-Cu is not part of that policy. FDA lists GHK-Cu in category 1 only for routes other than injection, and plans an advisory committee meeting on GHK-Cu before the end of February 2027.[21][22]

  1. FDA places BPC-157 and TB-500 in category 2, the significant safety concerns group.[3]
  2. The category 2 status of BPC-157 and TB-500 ends on April 22, 2026.[3]
  3. Advisory committee votes 8 to 6 with one abstention on each of BPC-157 and TB-500, in separate votes.[19]
  4. HHS files an enforcement discretion policy that covers six peptides as single ingredient products only, set for publication on October 30.[20][3]
  5. FDA plans to ask its advisers about GHK-Cu.[22]

Sources

  1. U.S. Food and Drug Administration. FDA Briefing Document for BPC-157-Related Bulk Drug Substances. Pharmacy Compounding Advisory Committee Meeting, July 23-24, 2026. FDA briefing document, BPC-157
  2. Biçer O, Adanir O, Güleryüz Y, et al. Effects of BPC-157 and TB-500 on Achilles tendon healing in rats: A histopathological and biomechanical study. Jt Dis Relat Surg. 2026;37(3):822-837. PMID 42542926
  3. U.S. Department of Health and Human Services. HHS Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances, with Appendices A and B. October 2026. HHS policy document
  4. U.S. Food and Drug Administration. FDA Briefing Document for TB-500-Related Bulk Drug Substances. Pharmacy Compounding Advisory Committee Meeting, July 23-24, 2026. FDA briefing document, TB-500
  5. Pickart L, Margolina A. Regenerative and Protective Actions of the GHK-Cu Peptide in the Light of the New Gene Data. Int J Mol Sci. 2018;19(7):1987. doi 10.3390/ijms19071987
  6. Schagen SK. Topical Peptide Treatments with Effective Anti-Aging Results. Cosmetics. 2017;4(2):16. doi 10.3390/cosmetics4020016
  7. Stone W. The copper peptide trend has gone from creams to injections ahead of the science. NPR, September 7, 2026 (republished by KPBS). NPR news report
  8. Hsieh MJ, Liu HT, Wang CN, et al. Therapeutic potential of pro-angiogenic BPC157 is associated with VEGFR2 activation and up-regulation. J Mol Med (Berl). 2017;95(3):323-333. PMID 27847966
  9. Lee E, Padgett B. Intra-Articular Injection of BPC 157 for Multiple Types of Knee Pain. Altern Ther Health Med. 2021;27(4):8-13. PMID 34324435
  10. Vasireddi N, Hahamyan H, Salata MJ, et al. Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review. HSS J. 2025;21(4):485-495. PMID 40756949
  11. Poolton JT, Minett J, Kazmi A. Human evidence for BPC-157 in orthopaedic and regenerative medicine: a systematic review of efficacy and safety. Acta Orthop Belg. 2026;92(3). PMID 42885452
  12. Guarnera G, DeRosa A, Camerini R, et al. The effect of thymosin treatment of venous ulcers. Ann N Y Acad Sci. 2010;1194:207-212. PMID 20536470
  13. Sosne G, Ousler GW, et al. Thymosin beta 4 ophthalmic solution for dry eye: a randomized, placebo-controlled, Phase II clinical trial conducted using the controlled adverse environment (CAE) model. Clin Ophthalmol. 2015;9:877-884. doi 10.2147/OPTH.S80954
  14. The Pharma Letter. ProCyte's lead product no better than placebo. October 1994. Trade news
  15. Froum S, Estrin N, Pico G, Yakubov M, Ahmad P, LaValle J. Case Report: Regenerative peptides for Inferior alveolar nerve injury: a narrative review with hypothesis-generating three clinical cases. Front Oral Health. 2026;7:1907109. PMID 42876687
  16. Moiz A, O'Keefe EL, O'Keefe JH. Dangers of Injectable Peptides and Other Unregulated "Biohacking" Drugs. Mo Med. 2026;123(4):337-343. PMID 42757290
  17. World Anti-Doping Agency. The 2026 Prohibited List. Effective 1 January 2026. WADA 2026 List
  18. World Anti-Doping Agency. The 2027 Prohibited List. Comes into effect 1 January 2027. WADA 2027 List
  19. Steinzor P. FDA Panel Backs 6 Peptides for Compounding. The American Journal of Managed Care. July 31, 2026. PCAC vote coverage
  20. Department of Health and Human Services, Office of the Secretary. Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances. Federal Register notice of availability, FR Doc. 2026-22192, filed October 28, 2026. Federal Register 2026-22192
  21. U.S. Food and Drug Administration. Bulk Drug Substances Nominated for Use in Compounding Under Section 503A of the Federal Food, Drug, and Cosmetic Act. Updated May 14, 2026. FDA 503A bulks list
  22. U.S. Food and Drug Administration. Meeting of the Pharmacy Compounding Advisory Committee (meeting planned before the end of February 2027). Content current as of April 15, 2026. FDA advisory committee page
Medical disclaimer

This page is educational information only. It is not medical advice and does not replace care from a licensed medical provider. Do not use this page to decide whether to take any substance. Talk to a licensed medical provider first.

Found an error or a newer study? We correct pages fast.

Report a correction →
Scroll to Top